Search

This study presents a comprehensive analysis of vehicle ownership, energy consumption, and carbon emissions in Guangdong Province, China, from 2020 to 2035 under different scenarios. Key findings highlight the province's pursuit of carbon peak goals and provide valuable insights into strategies to achieve them. Vehicle ownership in Guangdong is projected to exceed 48 million by 2035, which represents a doubling from 2020. Under both scenarios, internal combustion engine vehicle ownership will peak around 2030 and then gradually decline, while under the enhanced scenario, electric vehicle ownership will exceed 40% by 2035. Enhanced vehicle energy efficiency and reduced annual mileage will lead to a 17% reduction in gasoline and diesel consumption by 2035 in both scenarios. At the same time, there will be a substantial five- to six-fold increase in electricity consumption for vehicles compared to 2020. Both scenarios peak in carbon emissions before 2030, with the enhanced scenario achieving this peak a year earlier. The enhanced scenario outperforms the baseline, reducing carbon emissions by about 21.2% from the peak and 8% relative to 2020. Pure electric vehicles exhibit a significant advantage in reducing carbon emissions per vehicle compared to their internal combustion engine counterparts. Encouraging new energy vehicles, especially pure electric ones, accelerates the carbon emissions peak and lowers overall peak emissions. Accelerating the adoption of electric vehicles, reducing per-vehicle fuel consumption and annual average mileage, and optimizing transportation modes are crucial for carbon peaking from the vehicle fuel cycle. Policy recommendations focus on promoting new energy vehicles, optimizing transportation, and advancing research and technology. [ABSTRACT FROM AUTHOR]

The pathogenesis of temporomandibular joint osteoarthritis (TMJOA) is closely associated with mechanical friction, which leads to the up-regulation of inflammatory mediators and the degradation of articular cartilage. Injectable drug-loaded microparticles have attracted widespread interest in intra-articular treatment of TMJOA by providing lubrication and facilitating localized drug delivery. Herein, a hyaluronic acid-based microparticle is developed with excellent lubrication properties, drug loading capacity, antioxidant activity, and anti-inflammatory effect for the treatment of TMJOA. The microparticles are facilely prepared by the self-assembly of 3-aminophenylboronic acid-modified hyaluronic acid (HP) through hydrophobic interaction in an aqueous solution, which can further encapsulate diol-containing drugs through dynamic boronate ester bonds. The resulting microparticles demonstrate excellent injectability, lubrication properties, radical scavenging efficiency, and antibacterial activity. Additionally, the drug-loaded microparticles exhibit a favorable cytoprotective effect on chondrocyte cells in vitro under an oxidative stress microenvironment. In vivo experiments validate that intra-articular injection of drug-loaded microparticles effectively alleviates osteoporosis-like damage, suppresses inflammatory response, and facilitates matrix regeneration in the treatment of TMJOA. The HP microparticles demonstrate excellent injectability and encapsulation capacity for diol-containing drugs, highlighting its potential as a versatile drug delivery vehicle in the intra-articular treatment of TMJOA., Competing Interests: Competing interests: The authors declare that they have no competing interests., (Copyright © 2024 Lei Liu et al.)

Objective: Severe pancreatitis presents a formidable clinical challenge, often associated with high mortality rates and compromised quality of life. This study aimed to assess the efficacy of combining ulinastatin with somatostatin in treating severe pancreatitis, with a focus on improving patient outcomes., Methods: We conducted a study on 98 severe pancreatitis patients at our hospital from January 2022 to March 2023. These patients were randomly divided into two groups: a control group (n=49) treated with somatostatin and an experimental group (n=49) treated with ulinastatin plus somatostatin. The control group received 250 micrograms per hour of somatostatin intravenously for 72 hours. The experimental group received 200 000 units of ulinastatin every 8 hours intravenously, along with the same somatostatin regimen. We compared clinical efficacy, inflammatory markers (TNF-α, CRP, IL-6), hemodynamic parameters (MAP, CVP, HR, SVR), and immune cell function between the groups., Results: Post-treatment, the experimental group showed significant improvements compared to the control group (P < .05) in various parameters. Decreases in AMS, TNF-α, CRP, IL-6, MAP, CVP, and CD8+ T-cells were more pronounced in the experimental group. Notably, AMS levels dropped from 450 U/L to 150 U/L, and TNF-α levels from 55 pg/mL to 20 pg/mL in the experimental group. Conversely, increases in HR, SVR, CD4+ T-cells, CD4+/CD8+ ratio, and NK cell counts were observed. For instance, CD4+ T-cells rose from 300 cells/μL to 500 cells/μL. The experimental group exhibited a higher clinical efficacy rate of 97.96%, compared to 85.71% in the control group. The combined treatment of ulinastatin with somatostatin demonstrated significant effectiveness in improving clinical outcomes compared to the control group. Statistical analysis robustly supported these findings, providing confidence in their reliability. Importantly, the combined therapy showed promise in reducing mortality rates and enhancing the quality of life for patients with severe pancreatitis., Conclusion: The findings of this study hold substantial clinical implications, potentially influencing treatment protocols and patient management strategies for severe pancreatitis. The integration of ulinastatin combined with somatostatin into standard care protocols could significantly improve treatment outcomes and patient prognosis.